Jerome Abelman to Step Down as General Counsel of British American Tobacco After 23-Year Career; Paul McCrory Named as Successor

Sep.12
British American Tobacco (BAT) has announced that Legal Director and General Counsel Jerome Abelman will leave in late 2025 after 23 years. He will be succeeded in 2026 by Paul McCrory, the current Director of Corporate and Regulatory Affairs. CEO Tadeu Marroco commended Abelman’s service and stated the transition supports the group’s strategic priorities.

Key Points:

 

·High-level departure: Jerome Abelman will resign on December 31, 2025, ending his 23-year career at BAT. 

·Succession plan: Paul McCrory will take over as General Counsel starting January 1, 2026, having worked at BAT for 18 years and held positions such as Company Secretary. 

·Leadership feedback: The CEO praised Abelman's achievements in global legal compliance and team building, noting that the new appointment aims to strengthen legal leadership and strategic alignment.

 


 

In a press release dated September 12, 2025, British American Tobacco (BAT) announced that Jerome Abelman will be stepping down from his role as Chief Legal Officer and member of the management committee on December 31, 2025. This marks the end of Abelman's 23-year career at BAT, where he has served for over a decade in various legal positions.

 

Starting from January 1, 2026, the current Director of Corporate and Regulatory Affairs, Paul McCrory, will assume the position. Paul has been a member of the management board since September 1, 2023, with over 18 years of experience at British American Tobacco. Throughout his professional career, he has held several senior legal roles within the company, including positions in the Asia-Pacific region and 6 years serving as Corporate Secretary. Paul will first be appointed as the General Counsel Designate on October 1, 2025, and will continue to serve as a member of the management board.

 

Starting on October 1, 2025, the responsibilities of Corporate and Regulatory Affairs Director will be transferred to Chief Corporate Officer Kingsley Wheaton.

 

CEO Tadeu Marroco stated:

 

I express my sincere gratitude to Jerry for his contributions during his 23-year career at British American Tobacco, including an 11-year tenure as a member of the management board and General Counsel. Jerry's leadership has always guided the group to uphold its commitment to integrity in business operations. Welcome Paul to his new role. His nearly two decades of legal and regulatory experience at British American Tobacco, as well as this appointment, underscore the group's commitment to maintaining strong legal leadership aligned with strategic priorities. Paul's collaborative and inclusive leadership style, combined with his deep understanding of the global legal and regulatory environment, make him particularly well-suited to lead British American Tobacco's legal function into the future. As part of the expanded responsibilities of the Chief Corporate Officer role, Kingsley will build on the significant progress made by Paul to further sharpen the execution of our regulatory affairs and communications agenda.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

InterTabac 2025 Insights|Brands like NYSM and KIWI are promoting small-sized e-cigarettes, none of which feature screens
InterTabac 2025 Insights|Brands like NYSM and KIWI are promoting small-sized e-cigarettes, none of which feature screens
Inter Tabac 2025, held in Dortmund, Germany, took place from September 18th to 20th. 2Firsts observed that some booths, including those of NYSM, KIWI, Mevol, and FLERBAR, showcased small e-cigarettes. These devices were smaller or thinner than traditional disposable or cartridge-based e-cigarettes and lacked screen functionality.
Sep.23 by 2FIRSTS.ai
UK Shopkeeper Fined for Selling Illegal Vapes as Council Warns of Jail Time
UK Shopkeeper Fined for Selling Illegal Vapes as Council Warns of Jail Time
A North Yorkshire retailer and its director were convicted for selling over-strength and improperly labelled vapes, prompting a warning from trading standards that selling illegal vaping products could lead to fines or imprisonment.
Sep.09
Tunisia's tobacco control policies are insufficiently implemented; experts call for the introduction of less harmful alternatives to help quit smoking
Tunisia's tobacco control policies are insufficiently implemented; experts call for the introduction of less harmful alternatives to help quit smoking
Although Tunisia has joined the WHO Framework Convention on Tobacco Control and implemented policies such as smoking bans and advertising restrictions, insufficient enforcement means nearly half of all men still smoke, with youth being particularly vulnerable. Public health experts recommend that Tunisia learn from the experiences of Sweden and the United Kingdom, introduce less harmful alternatives, and establish a customized regulatory system.
Sep.30 by 2FIRSTS.ai
Georgia Lawmakers Propose Tobacco Tax Hike and Flavored Vape Ban, Legislation May Reach Vote in 2026
Georgia Lawmakers Propose Tobacco Tax Hike and Flavored Vape Ban, Legislation May Reach Vote in 2026
A bipartisan panel in the Georgia House of Representatives is weighing new anti-tobacco measures, including a cigarette tax hike, flavored e-cigarette ban, and stricter licensing rules. Lawmakers say the bill could be introduced in 2026, though the plan faces resistance in an election year.
Sep.01 by 2FIRSTS.ai
Brazil: Americana Councilor Proposes Ban on Vaping in Public Places
Brazil: Americana Councilor Proposes Ban on Vaping in Public Places
On September 1, Wagner Rovina, a councilor in Americana, Brazil, submitted a bill to the city council proposing a ban on the use of electronic cigarettes in public places, including squares, parks, schools, restaurants, and cinemas. The proposal is expected to go to a vote soon. It aims to strengthen oversight, protect public health, and prevent underage vaping.
Sep.02 by 2FIRSTS.ai
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai